Protein content as a marker for response to therapy in brain cancer
Brain tumors vary widely in how they respond to treatment. However, early assessment of therapy response is essential in order to choose the best possible treatment for the patient. Scientists from the German Cancer Research Center (DKFZ) have now been able to show in a study using non-invasive high-resolution 7-Tesla MRI scans that the protein content of tumors correlates with response to treatment and survival.
Read more ...
Could medical marijuana help grandma and grandpa with their ailments?
Medical marijuana may bring relief to older people who have symptoms like pain, sleep disorders or anxiety due to chronic conditions including amyotrophic lateral sclerosis, Parkinson's disease, neuropathy, spinal cord damage and multiple sclerosis, according to a preliminary study released today that will be presented at the American Academy of Neurology's 71st Annual Meeting in Philadelphia, May 4 to 10, 2019.
Read more ...
New treatment offers potentially promising results for the possibility of slowing, stopping, or even reversing Parkinson's disease
A pioneering clinical trials program that delivered an experimental treatment directly to the brain offers hope that it may be possible to restore the cells damaged in Parkinson's disease. The study investigated whether boosting the levels of a naturally-occurring growth factor, Glial Cell Line Derived Neurotrophic Factor (GDNF), can regenerate dying dopamine brain cells in patients with Parkinson's and reverse their condition, something no existing treatment can do.
Read more ...
Could blockchain ensure integrity of clinical trial data?
UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an immutable audit trail that makes it easy to spot any tampering with results - such as making the treatment look more effective or diminishing side effects.
Read more ...
New drug for Duchenne muscular dystrophy clears phase 1 clinical trial
Patients with Duchenne muscular dystrophy (DMD) have few treatment options. Medications currently available or in development either target only a subset of DMD patients with a particular genetic mutation or cause significant side effects. The investigational drug edasalonexent, an oral NF-κB inhibitor, has the potential to slow the progression of the disease for all patients with DMD.
Read more ...
Salt could be a key factor in allergic immune reactions
Salt apparently affects allergic immune reactions. A team working with Prof. Christina Zielinski at the Technical University of Munich (TUM) has demonstrated in cell cultures that salt leads to the formation of Th2 cells. These immune cells are active in allergic conditions such as atopic dermatitis. The team also detected elevated salt concentrations in the skin of patients.
Read more ...
New machine learning technique rapidly analyzes nanomedicines for cancer immunotherapy
With their ability to treat a wide a variety of diseases, spherical nucleic acids (SNAs) are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components. A Northwestern University team led by nanotechnology pioneer Chad A. Mirkin has developed a direct route to optimize these challenging particles,
Read more ...